FindTrial
Sign In

Usefulness of a test known as CBNAAT to diagnose TB of skin and to see if the bacteria will respond to a drug known as rifampicin

ROLE OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST (CBNAAT) IN THE RAPID DIAGNOSIS OF CUTANEOUS TUBERCULOSIS AND DETECTION OF RIFAMPICIN RESISTANCE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/01/022816
Enrollment
20
Registered
2020-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

None listed

Sponsors

DEPARTMENT OF DERMATOLOGY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients diagnosed clinically, histopathologically or using culture as any form of cutaneous tuberculosis. 2. Newly diagnosed patients of cutaneous TB and treatment started upto 8 weeks.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Evaluation of the role of CBNAAT in the rapid diagnosis of cutaneous tuberculosis and detection of rifampicin resistanceTimepoint: 24 hours—

Secondary

MeasureTime frame
To study the association of resistance pattern with the clinico-pathological presentation of the diseaseTimepoint: 1 year—

Countries

India

Contacts

Public ContactAnjali Bagrodia

Maulana Azad medical college

blsahoomamc@gmail.com9968604368

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026